Login
← Go Back
Divi's Laboratories
DIVISLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Ramesh BV Nimmagadda · MD: Murali K Divi · Listing date: March 12, 2003 · Employees: 16818 · Hyderabad · http://www.divislabs.com
Stock Price vs Company Growth
1d
1.4%
1w
3.1%
1m
3.0%
3m
24.5%
6m
45.3%
1y
37.9%
5y
12.5%
10y
22.6%
all
23.9%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 9,090 1.4%
7,178
10,000
Company Overview
Sales
11,230 Cr
Growth: 11.8%
Profit after Tax
2,925 Cr
Growth: 13.9%
Large Cap
2,41,311 Cr
P/E: 103.0x
Industry P/E: 32.5x
Fundamentals
Sales (Cr) ₹ 11,230
Growth 11.8%
EBITDA 35.3%
P/S 21.5x
Dividend 0.5%
P/E 103.0x
Book Value ₹ 665
PEG Ratio 8.9x
ROE 17.4%
P/B 13.9x
Shareholding Pattern
Institutions
Sbi Mutual Fund
4.49 %
Qualified Institutional Buyer
3.57 %
Axis Mutual Fund Trustee Ltd
3.37 %
Government Pension Fund Global
1.29 %
Life Insurance Corporation Of India
1.15 %
Promoters
Nilima Prasad Divi
20.34 %
Divi Satchandra Kiran
20.34 %
Divi Swarna Latha
5.27 %
Divi'S Biotech Private Limited
3.01 %
Murali Krishna Prasad Divi
2.85 %
Others
Increase    Decrease    No change
Company Profile Detailed
The company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generics, the Company, through its custom synthesis, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
Belongs to (58 Indices) view more
Investors (142)
credit.s...
m.sriniv...
y.vamsi....
Followers (42)
deepak
jayapras...
nitin2